For the fiscal year ending March 2026, consolidated net sales were \u00a5126.257 billion (a decrease of 2.9% YoY), operating income was \u00a53.567 billion (down 71.6% YoY), and net income attributable to owners of the parent was \u00a53.448 billion (down 62.0% YoY).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4569","jir_company_name":"Kyourin Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4569-20260512-01.pdf","jir_short_summary":"For the fiscal year ending March 2026, consolidated net sales were \u00a5126.257 billion (a decrease of 2.9% YoY), operating income was \u00a53.567 billion (down 71.6% YoY), and net income attributable to owners of the parent was \u00a53.448 billion (down 62.0% YoY).","jir_summary":"### Performance Overview\nFor the fiscal year ending March 2026, consolidated net sales were \u00a5126.257 billion (a decrease of 2.9% YoY). While sales of new pharmaceuticals (domestic) increased by 3.5%, the sales decline was offset by a reactionary decrease in contract up-front payments for new pharmaceuticals (overseas) and an increase in generic drug sales, resulting in overall revenue decline. Operating income was \u00a53.567 billion (down 71.6%), ordinary income was \u00a54.031 billion (down 69.5%), and net income attributable to owners of the parent was \u00a53.448 billion (down 62.0%), reflecting significant profit decrease. R&D expenses increased by 14.7% to \u00a512.060 billion, emphasizing efforts to expand the pipeline of new drugs.\n\n### Financial Position and Cash Flows\nTotal assets increased by \u00a51.836 billion from the previous year to \u00a5195.455 billion. Net assets rose by 2.5 percentage points to \u00a5142.425 billion, with the equity ratio standing at 72.9%. Cash flows from operating activities generated \u00a56.381 billion, investing activities used \u00a51.644 billion, and financing activities used \u00a57.956 billion, resulting in a cash and cash equivalents balance of \u00a511.802 billion at period-end.\n\n### Earnings Forecast for Next Fiscal Year\nFor the fiscal year ending March 2027, consolidated earnings are forecasted to be \u00a5121.8 billion (down 3.5% YoY) in net sales, \u00a52.0 billion (down 43.9%) in operating income, \u00a52.3 billion (down 42.9%) in ordinary income, and \u00a51.5 billion (down 56.5%) in net income attributable to owners of the parent. The forecast assumes an exchange rate of 1 USD = \u00a5152 and 1 EUR = \u00a5179.","jir_financial_highlights":"Net Sales: \u00a5126,257 million (\u25b32.9% YoY)\nOperating Income: \u00a53,567 million (\u25b371.6% YoY)\nOrdinary Income: \u00a54,031 million (\u25b369.5% YoY)\nNet Income Attributable to Owners of the Parent: \u00a53,448 million (\u25b362.0% YoY)\nNumber of Issued Shares (Common Stock): 59,945,641 shares (Decrease from previous fiscal year (64,607,936 shares \u2192 59,945,641 shares))\nNumber of Treasury Shares: 2,499,346 shares (Decrease from previous fiscal year (7,159,087 shares \u2192 2,499,346 shares))\nAnnual Dividends: \u00a557.00 (Same as previous fiscal year)\nEarnings Guidance for Next Fiscal Year - Net Sales: \u00a5121.8 billion (\u25b33.5% YoY)\nEarnings Guidance for Next Fiscal Year - Operating Income: \u00a52.0 billion (\u25b343.9% YoY)\nEarnings Guidance for Next Fiscal Year - Net Income Attributable to Owners of the Parent: \u00a51.5 billion (\u25b356.5% YoY)","jir_category":"","jir_hashtags":"#KyourinPharmaceutical, #FinancialSummary, #JapanStocks","jir_key_figures":"Net Sales: \u00a5126,257 million (\u25b32.9% YoY)\nOperating Income: \u00a53,567 million (\u25b371.6% YoY)\nNet Income Attributable to Owners of the Parent: \u00a53,448 million (\u25b362.0% YoY)","jir_meta_title":"\u3010Kyourin Pharmaceutical\u3011Fiscal Year 2026 Financial Results \uff5c Net Sales \u00a5126.2 billion (\u25b32.9% YoY)","jir_meta_description":"Kyourin Pharmaceutical's fiscal year 2026 financial summary. Net sales were \u00a5126,257 million (a 2.9% decrease YoY), operating income was \u00a53.567 billion (a 71.6% decrease), and net income attributable to owners of the parent was \u00a53.448 billion (a 62.0% decrease).","jir_og_title":"\u3010Kyourin Pharmaceutical\u3011Fiscal Year 2026 Financial Results \uff5c Net Sales \u00a5126.2 billion (\u25b32.9% YoY)","jir_og_description":"Kyourin Pharmaceutical's fiscal year 2026 financial summary. Net sales were \u00a5126,257 million, operating income was \u00a53.567 billion, and net income attributable to owners of the parent was \u00a53.448 billion.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ending March 2025\\\",\\\"Fiscal Year Ending March 2026\\\",\\\"Forecast for March 2027\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[130087,126257,121800],\\\"borderColor\\\":\\\"#007bff\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ending March 2025\\\",\\\"Fiscal Year Ending March 2026\\\",\\\"Forecast for March 2027\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[12567,3567,2000],\\\"borderColor\\\":\\\"#28a745\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Attributable to Owners of the Parent Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal Year Ending March 2025\\\",\\\"Fiscal Year Ending March 2026\\\",\\\"Forecast for March 2027\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[9086,3448,1500],\\\"borderColor\\\":\\\"#dc3545\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":16660,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-48156","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n